[Management of severe psoriasis: about 50 cases].
BACKGROUND
With its varied clinical presentation, psoriasis is actually considered as a public health care problem. Severe psoriasis remains difficult to treat.


METHODS
Our study was retrospective involving 50 patient with severe psoriasis treated in the dermatology unit of military hospital of Tunis from January 1990 to December 2003. Aim of our study was to evaluate actual different therapeutic attitudes and new treatments in case of severe psoriasis.


RESULTS
During the 14 years studied the frequency of severe psoriasis was about 19.5%. Extended psoriasis was noticed on 64% of the patients. Arthropatic psoriasis was found on only 6% of the patients. Erythrodermic psoriasis, pustular psoriasis and palmoplantar psoriatic keratoderma were equally noticed in 10% of the patients. PUVA-therapy was firstly prescribed on 96.6% of the patients with extended psoriasis, bettering was noticed on 71% of all them during the 3 first cures. From the 20 patients that have received acitretin, 65% have noticed improvement. Méthotrexate and Re-PUVA was secondarily used (only for the cases of psoriasic arthritis amd méthotrexate) on respectively 18% and 10% of the patients. All our patients reported worsening on thems quality of life.


CONCLUSIONS
Cyclosporin is more and more used initially in cases of rebellious psoriasis. Actually therapeutic hope leans on biological therapies.
Daoud
L
L
Service de Dermatologie, Hopital Militaire de Tunis.
Dhaoui
M R
MR
Youssef
S
S
Jaber
K
K
Doss
Néjib
N
D017255:Acitretin / Q000627:therapeutic use; D000293:Adolescent; D000328:Adult; D000368:Aged; D015535:Arthritis, Psoriatic / Q000188:drug therapy; D002648:Child; D003873:Dermatitis, Exfoliative / Q000188:drug therapy; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007641:Keratolytic Agents / Q000627:therapeutic use; D008297:Male; D008727:Methotrexate / Q000627:therapeutic use; D008875:Middle Aged; D011701:PUVA Therapy; D011565:Psoriasis / Q000145:classification / Q000188:drug therapy*; D011788:Quality of Life; D012176:Retinoids / Q000627:therapeutic use; D012189:Retrospective Studies; D016896:Treatment Outcome
D007641:Keratolytic Agents; D012176:Retinoids; D017255:Acitretin; D008727:Methotrexate